Strategies for Helicobacter pylori eradication: comparative effectiveness and pharmacoeconomic rationality
HERALD of North-Western State Medical University named after I.I. Mechnikov · 30.03.2026 · 18 (1) · 43-51
DOI: 10.17816/mechnikov702237 ↗Kurz gefasst
Fachartikel in der Zeitschrift HERALD of North-Western State Medical University named after I.I. Mechnikov, online erschienen am 30.03.2026. Verfasst von Arthur M. Veliev und 3 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: In clinical practice, it is critically important to continuously evaluate both the clinical effectiveness and the economic justification of the treatment regimens used. This involves collecting information on treatment outcomes, eradication rates, adverse effects, and treatment costs. Continuous monitoring makes it possible to adapt clinical practice to changing conditions, new data, and technological advances, thereby maintaining a high level of quality and effectiveness of medical care. AIM: To update the pharmacoeconomic data of three eradication therapy regimens: classic triple therapy, bismuth-containing quadruple therapy, and bismuth-free quadruple therapy under current price conditions. METHODS: Within the framework of a prospective cohort study, 210 patients with Helicobacter pylori-associated gastric or duodenal ulcer, male and female, residing in Moscow and the Moscow region, were examined. A significant stage of the study was the pharmacoeconomic analysis of various eradication regimens. RESULTS: During the pharmacoeconomic analysis, the cost-effectiveness ratio (CER) for classic triple therapy was 32.7, for bismuth-containing quadruple therapy CER = 31.9, and for bismuth-free quadruple therapy CER = 29.9. Thus, according to the results of the present study, four-component eradication therapy regimens can be considered the most clinically and economically optimal. CONCLUSION: The results of the study showed that four-component therapy regimens have an advantage in eradication effectiveness without a significant increase in costs, making them more preferable within the current treatment conditions. The pharmacoeconomic analysis revealed that consideration of drug costs, the risk of adverse events, and the likelihood of repeated courses significantly influences the final choice of strategy. Given differences in prices, drug availability, and resistance of Helicobacter pylori strains, four-component regimens demonstrate the best overall economic feasibility.
Zitieren
APA
Veliev, A. M., Pavleeva, E. E., Lebedeva, E. G., & Vyuchnova, E. S. (2026). Strategies for Helicobacter pylori eradication: comparative effectiveness and pharmacoeconomic rationality. HERALD of North-Western State Medical University named after I.I. Mechnikov, 18(1), 43-51. https://doi.org/10.17816/mechnikov702237
Vancouver
Veliev AM, Pavleeva EE, Lebedeva EG, Vyuchnova ES. Strategies for Helicobacter pylori eradication: comparative effectiveness and pharmacoeconomic rationality. HERALD of North-Western State Medical University named after I.I. Mechnikov. 2026;18(1):43-51. doi:10.17816/mechnikov702237
BibTeX
@article{Veliev2026,
author = {Veliev, Arthur M. and Pavleeva, Elena E. and Lebedeva, Ekaterina G. and Vyuchnova, Elena S.},
title = {Strategies for Helicobacter pylori eradication: comparative effectiveness and pharmacoeconomic rationality},
journal = {HERALD of North-Western State Medical University named after I.I. Mechnikov},
year = {2026},
volume = {18},
number = {1},
pages = {43--51},
doi = {10.17816/mechnikov702237}
}
EUVIMED